نتایج جستجو برای: her2 amplification

تعداد نتایج: 71537  

Abolghasem Esmaeili, Hosein Tabatabaeian, Majid Motovali-Bashi, Zeinab Hallajian, Zohreh Hojati,

Background: Amplification of HER2 is seen in 20-30% of breast cancer cases. Measurement of HER2 gene amplification appears to be of vital importance in planning the treatment schedule for patients with breast carcinoma. The aim of our study was to evaluate HER2 amplification status in malignant and benign breast tumors by differential PCR (dPCR). Materials and Methods: The genomic DNA was ex...

Journal: :research in molecular medicine 0
zohreh hojati genetics division, biology department, faculty of sciences, university of isfahan, isfahan, iran zeinab hallajian genetics division, biology department, faculty of sciences, university of isfahan, isfahan, iran abolghasem esmaeili genetics division, biology department, faculty of sciences, university of isfahan, isfahan, iran majid motovali-bashi genetics division, biology department, faculty of sciences, university of isfahan, isfahan, iran hosein tabatabaeian genetics division, biology department, faculty of sciences, university of isfahan, isfahan, iran

background: amplification of her2 is seen in 20-30% of breast cancer cases. measurement of her2 gene amplification appears to be of vital importance in planning the treatment schedule for patients with breast carcinoma. the aim of our study was to evaluate her2 amplification status in malignant and benign breast tumors by differential pcr (dpcr). materials and methods: the genomic dna was extra...

Background & Objective: The her2 amplification plays an important role in breast cancer management. Therefore, there is a need for using supplementary molecular methods in IHC equivocal cases. Present study has been conducted to determine the effects of clinicopathological variables on her2 gene amplification by chromogenic in situ hybridization (CISH) in IHC ...

Ardeshir Ghavamzadeh, Fatemeh Nevisi, Gholamreza Javadi, Hossein Pashaiefar, Kamran Alimoghaddam, Marjan Yaghmaie, Masoud Iravani,

Background: The analysis of the gene copy number alterations in tumor samples are increasingly used for diagnostic and prognostic purposes in patients with gastric cancer (GC). However, these procedures are not always applicable due to their invasive nature. In this study, we have analyzed the copy number alterations of five genes (HER2, MDM2, c-MYC, c-MET, and TP53) with a fixed relevance for ...

Ardeshir Ghavamzadeh, Fatemeh Nevisi, Gholamreza Javadi, Hossein Pashaiefar, Kamran Alimoghaddam, Marjan Yaghmaie, Masoud Iravani,

Background: Gastric cancer (GC) is considered as one of the most common types of cancer worldwide with poor prognosis and generally limited treatment options. Recent studies have indicated that HER2, MDM2, MYC, MET, and TP53 play an important role in the development of gastric cancer. Therefore, the aim of this study was to evaluate the incidence of amplification/deletion of these genes in pati...

Background and aims:  Gastric malignancies have the fourth place among the most prevalent cancers. In many cancers, overexpressing of HER2/neu gene has been observed with a poor prediction. Up to now, there is a little information about the duplication of HER2/neu gene in gastric cancer using MLPA method. The present study aimed to investigate the frequency of mutations resulting from ampl...

2017
Xiaoyu Hu Yanan Li Dong Yuan Ruohan Li Lingquan Kong Hongyuan Li Zhu Yang Qiubo Yu

The aim of the present study was to identify potential human epidermal growth factor receptor 2 (HER2) amplification, according to American Society of Clinical Oncology and the College of American Pathologists (ASCO/CAP) 2013 HER2 testing guidelines, in patients previously determined not to possess HER2 amplification, in accordance with previous 2007 guidelines. Potential discrepancies may aris...

2013
Sabina Berezowska Alexander Novotny Karina Bauer Annette Feuchtinger Julia Slotta-Huspenina Karen Becker Rupert Langer Axel Walch

BACKGROUND Her2 expression and amplification occurs in a significant subset of gastro-esophageal carcinomas. Her2 is a client protein of molecular chaperones, e.g. heat shock protein (HSP) 90, rendering targeted therapies against Her2/HSP90 an interesting approach. This study aimed to investigate the role and relationship of Her2 and HSP90 in gastric and gastro-esophageal adenocarcinomas. MAT...

Journal: :Oncology reports 2008
Makoto Kammori Rie Kurabayashi Mitsuhiko Kashio Akiko Sakamoto Masataka Yoshimoto Sadao Amano Michio Kaminishi Tetsu Yamada Kaiyo Takubo

An accurate investigation of the HER2 proto-oncogene is extremely important for the therapy and prognostication of breast cancer. Currently, immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) are standard methods for this purpose. The aim of this study was to detect the expression and amplification of HER2 in paraffin-embedded samples of breast cancer tissue and to investi...

Journal: :iranian red crescent medical journal 0
hanifeh mirtavoos mahyari chronic respiratory disease research center, national research institute of tuberculosis and lung disease (nritld), shahid beheshti university of medical sciences, tehran, ir iran adnan khosravi hematology and medical oncology, chronic respiratory disease research center, national research institute of tuberculosis and lung disease (nritld), shahid beheshti university of medical sciences, tehran, ir iran; hematology and medical oncology, chronic respiratory disease research center, national research institute of tuberculosis and lung disease (nritld), shahid beheshti university of medical sciences, tehran, ir iran. tel: +98-2126109946 zeinab mirtavoos mahyari tehran medical branch, islamic azad university, tehran, ir iran zahra esfahani monfared mycobacteriology research center, national research institute of tuberculosis and lung disease (nritld), shahid beheshti university of medical sciences, tehran, ir iran negin khosravi north tehran branch, azad university of tehran, tehran, ir iran

conclusions this study on a limited number of patients treated with adjutant anthracyclins-based regimens, revealed that her2/neu is not a unique strong predictor for outcome, thus according to combination of her2/neu status and other clinical factors, it is necessary to distinguish patients at high risk of recurrence. results her2/neu amplification was identified in 19 (38%) of 50 patients. no...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید